# Fulcrum Therapeutics (FULC) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/FULC
## Company Profile
- Ticker: FULC
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Small Molecule Drugs
## Stock Data
- Close: 3.72 USD
- Market cap: 209228627.94 USD
- Last updated: 2026-08-12
## Business Overview
### Gene-Expression Drug Discovery
Fulcrum Therapeutics develops small molecules that modulate gene expression in genetically defined diseases. Its current focus is rare hematologic disease and the use of oral therapy to alter red-blood-cell biology.
### Pociredir
Pociredir is an oral inhibitor of embryonic ectoderm development designed to increase fetal hemoglobin in sickle cell disease. Higher fetal hemoglobin can reduce hemoglobin polymerization, hemolysis, anemia and vaso-occlusive complications.
### Clinical Development Strategy
The PIONEER program demonstrated rapid fetal-hemoglobin induction and encouraging changes in disease markers. Fulcrum has also started a long-term study to assess durability and safety in previously treated participants while preparing a potentially registration-enabling trial.
## Why The Stock Is Moving

As of Aug 12, 2026, FULC closed up 0.81% at $3.72. No new same-company headline was identified in the current news window.

## Future Catalysts

- Update on the next pociredir trial design expected in the second quarter of 2026 following FDA meeting minutes.
- Initiation of a potential registration-enabling pociredir trial planned in the second half of 2026, pending FDA feedback.

## Recent News
- 2026-06-01 20:05 EST — [Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-announces-discontinuation-of-pociredir-program-in-sickle-ce-a4687a0d) — Source: Fulcrum Therapeutics
- 2026-05-08 20:30 EST — [Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--af9b71b6) — Source: Fulcrum Therapeutics
- 2026-04-27 11:00 EST — [Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results--b3f1692d) — Source: Fulcrum Therapeutics
- 2026-04-27 10:55 EST — [Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-appoints-josh-lehrer-to-its-board-of-directors-6c29e5a6) — Source: Fulcrum Therapeutics
- 2026-04-20 12:00 EST — [Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-to-host-first-quarter-2026-financial-results-conference-cal-42a5e6f1) — Source: Fulcrum Therapeutics